Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-053074
Filing Date
2026-05-07
Accepted
2026-05-07 08:30:52
Documents
60
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0288837-10q_cadrenal.htm   iXBRL 10-Q 508111
2 CERTIFICATION ea028883701ex31-1.htm EX-31.1 11444
3 CERTIFICATION ea028883701ex31-2.htm EX-31.2 11469
4 CERTIFICATION ea028883701ex32-1.htm EX-32.1 4753
5 CERTIFICATION ea028883701ex32-2.htm EX-32.2 4394
  Complete submission text file 0001213900-26-053074.txt   3994505

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cvkd-20260331.xsd EX-101.SCH 42655
7 XBRL CALCULATION FILE cvkd-20260331_cal.xml EX-101.CAL 22129
8 XBRL DEFINITION FILE cvkd-20260331_def.xml EX-101.DEF 177570
9 XBRL LABEL FILE cvkd-20260331_lab.xml EX-101.LAB 346445
10 XBRL PRESENTATION FILE cvkd-20260331_pre.xml EX-101.PRE 190426
63 EXTRACTED XBRL INSTANCE DOCUMENT ea0288837-10q_cadrenal_htm.xml XML 409324
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41596 | Film No.: 26951042
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)